Our tissue-based Mitomic Prostate Core Test™ receives positive results from an independent post-market study conducted by the prestigious uro-oncology trials management organization, CUSP Group.
Jupiter, FL, June 1, 2015 – MDNA Life Sciences Inc. (MDNA), a molecular diagnostics company pioneering the development of diagnostic tests based on the mitochondrial genome, announced today that it received positive results from an independent post-market study evaluating the clinical utility of its tissue-based Prostate Core Mitomic Test™ (PCMT), conducted by the prestigious CUSP Group, LLC Uro-Oncology Trials Management Organization.
Based on the use of PCMT in a “real-world” clinical setting, the results showed a five to 10-fold reduction in repeat biopsy rates in cases where PCMT gave a negative indication for prostate cancer. Publication of full results from the study is planned for early 2016, where it is expected to support future sales of PCMT and reimbursement of Medicare back claims based on sales of PCMT dating to 2013. About MDNA Life Sciences MDNA Life Sciences, Inc. is pioneering the development of molecular diagnostic tests based on the mitochondrial genome. The company’s revenue-generating Prostate Core Mitomic Test™ (PCMT™) is the highest performing tissue-based prostate cancer diagnostic on the market with a significantly greater tumor field effect that allows 85% sensitivity and 92% negative predictive value. MDNA is applying its expertise in mitochondrial genomics to developing an extensive and proprietary portfolio of blood-based molecular tests in conditions that are currently dependent on poor or absent screening tests or invasive procedures for detection. Blood-based diagnostic tests for prostate cancer and endometriosis are in late stage development.
For more information visit mdnalifesciences.com.